Cu(II)ATSM

DRUG5 trials

Sponsors

Collaborative Medicinal Development Pty Limited

Conditions

Amyotrophic Lateral SclerosisMotor Neuron DiseaseParkinson Disease

Phase 1

Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

CompletedNCT02870634

Collaborative Medicinal Development Pty LimitedAmyotrophic Lateral Sclerosis, Motor Neuron Disease

Start: 2016-11-16End: 2020-01-30Target: 50Updated: 2020-03-17

ALS Treatment Extension Study

Collaborative Medicinal Development Pty LimitedAmyotrophic Lateral Sclerosis

Start: 2018-01-18End: 2022-12-31Updated: 2022-02-17

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

CompletedNCT03204929

Collaborative Medicinal Development Pty LimitedParkinson Disease

Start: 2017-08-14End: 2020-02-29Updated: 2020-03-17

Phase 2

CuATSM Compared With Placebo for Treatment of ALS/MND

Collaborative Medicinal Development Pty LimitedAmyotrophic Lateral Sclerosis

Start: 2019-09-30End: 2020-12-30Target: 80Updated: 2019-11-06

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

CompletedNCT04313166

Collaborative Medicinal Development Pty LimitedAmyotrophic Lateral Sclerosis

Start: 2020-03-19End: 2022-02-15Updated: 2022-02-17